ArticleAdvances in therapy2024

Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain.

Manuel Botana López et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.